Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

被引：0
|
作者：
Meletios Dimopoulos
Michael Wang
Vladimir Maisnar
Jiri Minarik
William Bensinger
Maria-Victoria Mateos
Mihaela Obreja
Julie Blaedel
Philippe Moreau
机构：
[1] National and Kapodistrian University of Athens,School of Medicine
[2] The University of Texas MD Anderson Cancer Center,undefined
[3] Faculty Hospital and Medical Faculty of Charles University in Hradec Kralove,undefined
[4] University Hospital Olomouc,undefined
[5] Medical Faculty of Palacky University Olomouc,undefined
[6] Fred Hutchinson Cancer Research Center,undefined
[7] Hospital Clinico Universitario de Salamanca-IBSAL,undefined
[8] Amgen,undefined
[9] Inc.,undefined
[10] University of Nantes,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Clinical research; Clinical trials; Multiple myeloma; Myeloma therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
    Stewart, A. Keith
    Rajkumar, S. Vincent
    Dimopoulos, Meletios A.
    Masszi, Tamas
    Spicka, Ivan
    Oriol, Albert
    Hajek, Roman
    Rosinol, Laura
    Siegel, David S.
    Mihaylov, Georgi G.
    Goranova-Marinova, Veselina
    Rajnics, Peter
    Suvorov, Aleksandr
    Niesvizky, Ruben
    Jakubowiak, Andrzej
    San Miguel, Jesus F.
    Ludwig, Heinz
    Zojwalla, Naseem
    Tonda, Margaret E.
    Xing, Biao
    Moreau, Philippe
    Palumbo, Antonio
    BLOOD, 2014, 124 (21)
  • [22] Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.
    Biran, Noa
    Siegel, David Samuel DiCapua
    Berdeja, Jesus G.
    Raje, Noopur S.
    Cornell, Robert F.
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy
    Landgren, Carl Ola
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
    Stewart, A. Keith
    Dimopoulos, Meletios A.
    Masszi, Tamas
    Spicka, Ivan
    Oriol, Albert
    Hajek, Roman
    Rosinol, Laura
    Siegel, David S.
    Niesvizky, Ruben
    Jakubowiak, Andrzej J.
    San-Miguel, Jesus F.
    Ludwig, Heinz
    Buchanan, Jacqui
    Cocks, Kim
    Yang, Xinqun
    Xing, Biao
    Zojwalla, Naseem
    Tonda, Margaret
    Moreau, Philippe
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) : 3921 - +
  • [24] Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in real world patients with relapsed/refractory multiple myeloma: KMM2004 study
    Kim, Do Young
    Shin, Ho-Jin
    Min, Chang-Ki
    Eom, Hyeon-Seok
    Jung, Jongheon
    Kim, Kihyun
    Lee, Jae Hoon
    Yoo, Kwai Han
    Lee, Ji Yun
    Byun, Ja Min
    Kim, Sung-Hyun
    Lee, Ji Hyun
    Cho, Hee Jeong
    Lee, Sang Min
    Do, Young Rok
    Park, Sungwoo
    Lee, Junglim
    Lee, Seung-Shin
    Kang, Hye Jin
    Park, Young Hoon
    Lim, Sung-Nam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S189 - S190
  • [25] Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation: Secondary Analysis from the Phase 3 Aspire Study (NCT01080391)
    Hari, Parameswaran N.
    Song, Kevin
    Bensinger, William
    Siegel, David
    Davies, Faith
    Huang, Mei
    Iskander, Karim
    Aggarwal, Sanjay
    Abonour, Rafat
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S66 - S67
  • [26] KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients
    Salvatore Palmieri
    S. Rocco
    O. Vitagliano
    L. Catalano
    C. Cerchione
    I. D. Vincelli
    A. Scopelliti
    M. Gentile
    G. Farina
    M. Barone
    A. Gagliardi
    D. Esposito
    M. Arcamone
    V. Amico
    R. Fontana
    A. Sementa
    A. Sica
    G. Svanera
    F. Pane
    F. Ferrara
    Annals of Hematology, 2020, 99 : 2903 - 2909
  • [27] KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients
    Palmieri, Salvatore
    Rocco, S.
    Vitagliano, O.
    Catalano, L.
    Cerchione, C.
    Vincelli, I. D.
    Scopelliti, A.
    Gentile, M.
    Farina, G.
    Barone, M.
    Gagliardi, A.
    Esposite, D.
    Arcamone, M.
    Amico, V
    Fontana, R.
    Sementa, A.
    Sica, A.
    Svanera, G.
    Pane, F.
    Ferrara, F.
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2903 - 2909
  • [28] CARFILZOMIB AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL AND RESPONSE RATES VS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS (PTS) WITH RELAPSED MULTIPLE MYELOMA (RMM): THE PHASE 3 STUDY ENDEAVOR
    Dimopoulos, M.
    Moreau, P.
    Palumbo, A.
    Joshua, D.
    Pour, L.
    Hajek, R.
    Facon, T.
    Ludwig, H.
    Oriol, A.
    Goldschmidt, H.
    Rosinol, L.
    Straub, J.
    Suvorov, A.
    Araujo, C.
    Rimashevskaya, E.
    Pika, T.
    Gaidano, G.
    Weisel, K.
    Goranova-Marinova, V.
    Schwarer, A.
    Minuk, L.
    Masszi, T.
    Karamanesht, I.
    Offidani, M.
    Hungria, V.
    Spencer, A.
    Gillenwater, H.
    Mohamed, N.
    Feng, S.
    Chng, W. J.
    HAEMATOLOGICA, 2015, 100 : 336 - 336
  • [29] Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial
    Pelham, Robert J.
    Hu, Xuguang
    Moreau, Philippe
    Oriol, Albert
    Quach, Hang
    Kovacsovics, Tibor
    Keats, Jonathan J.
    Feng, Shibao
    Kimball, Amy S.
    Dimopoulos, Meletios A.
    BLOOD, 2017, 130
  • [30] Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
    Jiri Minarik
    Tomas Pika
    Jakub Radocha
    Alexandra Jungova
    Jan Straub
    Tomas Jelinek
    Ludek Pour
    Petr Pavlicek
    Martin Mistrik
    Lucie Brozova
    Petra Krhovska
    Katerina Machalkova
    Pavel Jindra
    Ivan Spicka
    Hana Plonkova
    Martin Stork
    Jaroslav Bacovsky
    Lenka Capkova
    Michal Sykora
    Petr Kessler
    Lukas Stejskal
    Adriana Heindorfer
    Jana Ullrychova
    Tomas Skacel
    Vladimir Maisnar
    Roman Hajek
    BMC Cancer, 21
12345